Terns Pharmaceuticals halts its TERN-601 obesity program due to insufficient efficacy and safety concerns. Click here to read ...
1dOpinion
Opinion: A wider look at kratom and Connecticut. Synthetic derivatives and natural leaves differ
While not risk-free, natural leaf kratom offers an accessible option, and many users report that it helps them regain control ...
October 30th is the day when Eli Lilly will report its third-quarter results, including sales of its 'superstars' Zepbound ...
Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with ...
In September 2024, Sanofi entered an exclusive licensing agreement with Orano Med and RadioMedix to globally commercialize ...
Inhibrx Biosciences’ antibody ozekibart has notched a key phase 2 win in a rare bone cancer that currently has no approved ...
Early research suggests a brain test may predict whether antidepressants will cause sexual dysfunction. There has never been ...
About Alpha Cognition Inc. Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as ...
Topline results were announced from a phase 3 trial evaluating BNC210 in patients with social anxiety disorder.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback